Home/Pipeline/MYO Platform (Metabolic Disease)

MYO Platform (Metabolic Disease)

Obesity

Pre-clinicalActive

Key Facts

Indication

Obesity

Phase

Pre-clinical

Status

Active

Company

Renbio

About Renbio

RenBio is a private, preclinical-stage biotech developing a disruptive DNA delivery platform called MYO Technology. The platform encodes therapeutic proteins or antibodies in DNA, which is administered via intramuscular injection and electroporation, instructing the patient's muscle to become a bioreactor for sustained, in vivo drug production. This approach seeks to overcome key limitations of traditional biologics, including frequent dosing, high manufacturing costs, and cold-chain logistics. The company, co-founded by renowned virologist Dr. David Ho, is initially targeting infectious diseases and metabolic conditions like obesity, with the goal of creating longer-lasting, more accessible therapies.

View full company profile

Therapeutic Areas

Infectious Diseases Metabolic Disease Obesity

Other Obesity Drugs

Drug	Company	Phase	Status
LET003	Harbour BioMed	Discovery	Active (Global)
LET001	Harbour BioMed	Discovery	Active (Global)
RGT-075	Regor Therapeutics	Phase 2b	Active
Anti‑Obesity Oral Drug	Premas Biotech	Phase 1	Active
Obesity Target Discovery Collaboration	Fauna Bio	Target Discovery/Preclinical	Active
GLP-1 variants	Heligenics	Discovery	Active
Obesity Clinical Trials	IMA Clinical Research	Not Applicable (Service)	Active
KAYO-2000	KayoThera	Preclinical	Active
MVD-1 (SANA)	Eolo Pharma	Phase 1	Active
GIP-neutralizing antibody	Helicore Biopharma	Pre-clinical	Active
Antral Gastroplasty / Endoscopic Sleeve	Endo-TAGSS	Pre-clinical	Active
Undisclosed siRNA Programs	Moonwalk Biosciences	Pre-clinical	Active